Mentice Acquires Endovascular Business From Medical Simulation Corporation


December 20, 2017—Mentice, a provider of simulation-based performance solutions for endovascular therapies, announced that it has acquired Medical Simulation Corporation's (MSC) Medical Products division in a share-based transaction. Mentice stated that with this acquisition, it boosts the company's development presence in the United States and adds a clinical training service line that will be leveraged in the Mentice VIST product line.

Mentice will immediately assume responsibility for MSC’s clients and will provide continued support for MSC's Compass AT and Compass 2 platforms along with associated software and iPad apps. Mentice also plans to offer migration solutions to the Mentice VIST platform. MSC’s Advanced Clinical Quality Solutions enable multidisciplinary health care team performance improvement, with a focus on standardizing care delivery and creating clinical and cost-control results.

According to Mentice, this transaction enables MSC to focus its efforts on its Hospital Performance Improvement division (HPI). Additionally, HPI services include consulting, online courseware, and clinical pathway training.

Mentice's virtual reality‐based interventional medical simulation solutions help health care professionals with skills acquisition, continuous development, and preprocedural planning, leading to improved productivity and outcomes. Mentice's solutions are applicable for neurovascular, cardiovascular, and peripheral interventions, as well as other areas.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.